PASSAGE

Official Title

A Multicenter, Single-arm, Open-label, Post-Authorization, Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants With Severe Asthma Including Several Under-Studied Populations in the United States (PASSAGE)

Study Purpose

To assess the effectiveness of tezepelumab in the United States (US) among a real-world population of adults participants with asthma requiring medium-dose to high-dose inhaled corticosteroids (ICS)

Diagnosis

Eligibility

• Male or female, older than 19 years
• Physician-diagnosed asthma for at least 12 months prior
• Use of medium- to high-dose inhaled corticosteroids for at least 12 months prior
• Use of additional asthma maintenance controller medications for at least 12 months prior
• History of at least 2 asthma exacerbations in the 12 months prior
• Cannot use biologic treatment for asthma within 4 months prior to consent
• Cannot be enrolled into another clinical trial for asthma within 12 months

Intervention

tezepelumab (Tezspire)